Navigation Links
PharmAthene to Host First Quarter 2008 Conference Call and Webcast on Tuesday, May 13, 2008
Date:5/6/2008

ANNAPOLIS, Md., May 6 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (Amex: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial results for the first quarter of 2008 will be released on Tuesday, May 13, 2008.

PharmAthene management will be hosting a conference call to discuss its first quarter 2008 financial results. The call is scheduled to begin at 4:30 p.m. Eastern Time on Tuesday, May 13, 2008 and will last approximately 45 minutes.

The dial-in number within the United States is 866-770-7129. The dial-in number for international callers is 617-213-8067. The participant passcode is 26177716.

A replay of the conference call will be available for 30 days, beginning at approximately 6:30 p.m. Eastern Time on May 13, 2008 until approximately 11:50 p.m. Eastern Time June 13, 2008. The dial-in number from within the United States is 888-286-8010. For international callers, the dial-in number is 617-801-6888. The participant passcode is 15975144.

The conference call will also be webcast and can be accessed from the company's website at http://www.pharmathene.com. A link to the webcast may be found on both the Home Page and also under the Investor Relations section of the website. The webcast will be available for 30 days, or until approximately June 13, 2008.

About PharmAthene, Inc.

PharmAthene (Amex: PIP) was formed in March 2001 with a mission to become the premier company worldwide specializing in the development and commercialization of therapeutic and prophylactic products for defense against biological and chemical threats. Since its inception, PharmAthene has pursued an acquisitive growth strategy focused on high priority, next generation biodefense products that the government has expressed a clear need and intent to procure. PharmAthene's portfolio currently includes five potential best- in-class biodefense medical countermeasures: Recombinant Protective Antigen (rPA) anthrax vaccine; Valortim(TM), an anthrax anti-toxin therapeutic which is being co-developed with Medarex; Protexia(R) a novel recombinant bioscavenger to prevent and treat organophosphorous nerve agent poisoning; RypVax(TM), a recombinant dual antigen plague vaccine; and finally, third generation rPA anthrax vaccine technology. For more information on PharmAthene, please visit http://www.PharmAthene.com.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
10. PharmAthene to Delay Release of Full Year 2007 Financial Results
11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... (PRWEB) , ... May 23, ... ... offer an unlimited source of human cardiovascular cells for research and the ... methods makes it possible to generate large numbers of cardiomyocytes (hPSC-CMs). Due ...
(Date:5/23/2017)... ... 2017 , ... Energetiq Technology, a world leader in high ... accommodate its rapid growth. , The renovations at the company’s headquarters in Woburn, ... areas. The expansion includes, a state-of-the-art engineering facility, and a second clean manufacturing ...
(Date:5/22/2017)... ... ... Stratevi, a boutique firm that partners with healthcare companies to creatively develop and ... downtown Boston at 745 Atlantic Ave. , “We are seeing that even the ... value they provide, not just to patients, but also payers. Having a presence in ...
(Date:5/19/2017)... ... , ... In response to the strong base of evidence supporting the use ... release of their Gait Trainer 3 with an Integrated Music Therapy option. This is ... in rehabilitating individuals with cerebral palsy, traumatic brain injury, stroke and Parkinson’s disease. ...
Breaking Biology Technology:
(Date:3/30/2017)... 2017  On April 6-7, 2017, Sequencing.com will host ... hackathon at Microsoft,s headquarters in Redmond, ... on developing health and wellness apps that provide a ... Genome is the first hackathon for personal genomics ... companies in the genomics, tech and health industries are ...
(Date:3/29/2017)... , March 29, 2017  higi, the health ... in North America , today announced ... and the acquisition of EveryMove. The new investment and ... set of tools to transform population health activities through ... lifestyle data. higi collects and secures data ...
(Date:3/24/2017)... MILAN , March 24, 2017 The Controller ... Deputy Controller Mr. Abdulla Algeen have received the prestigious international ... Continue Reading ... ... small picture) and Deputy Controller Abdulla Algeen (small picture on the right) ...
Breaking Biology News(10 mins):